Investors & Media
Our science-driven strategy allows us to advance our programs with sound execution and ultimately bring long-term value to patients. Follow the journey of our dedicated scientists and drug developers or learn how you can contribute to our mission.
Our science-driven strategy allows us to advance our programs with sound execution and ultimately bring long-term value to patients. Follow the journey of our dedicated scientists and drug developers or learn how you can contribute to our mission.
Investor Opportunities
Contact UsLatest News
신주발행공고
September 21, 2026
1ST Biotherapeutics and SK Biopharmaceuticals Announce Exclusive Global License Agreement for Parkinson’s Disease Candidate ‘1ST-104’
September 17, 2026
퍼스트바이오·SK바이오팜, 파킨슨병 치료 후보물질 ‘1ST-104’ 글로벌 독점 라이선스 계약 체결
September 17, 2026
신주발행공고
September 4, 2026
글로벌 SAB 출범… 릴리 R&D 수장 출신 얀 룬드베리 박사 합류
June 4, 2026
1STBIO, 릴리 튠랩(TuneLab) 협력 통해 파이프라인 개발 가속화
May 7, 2026
퍼스트바이오, AACR 2026서 HPK1 저해제 ‘FB849’ 항암 면역 활성화 기전 공개
April 1, 2026
2026년 제1회 임시주주총회 소집공고
March 13, 2026
퍼스트바이오·디앤디파마텍, ‘NLY02’ 유럽 특허 확보
March 11, 2026
